Investigating the role of Th9 cells in protecting against tuberculosis
Th9 cells and protective TB immunity
This study is looking at how a special type of immune cell called Th9 cells can help our bodies fight off tuberculosis (TB), and it's for people who have been vaccinated against TB or have a latent TB infection.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Saint Louis University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11044035 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific type of immune cell, known as Th9 cells, can help protect against tuberculosis (TB). The researchers will explore how these cells are activated and their potential to enhance immunity against Mycobacterium tuberculosis, the bacteria that causes TB. By studying immune responses in individuals who have been vaccinated or have latent TB infection, the team aims to uncover the mechanisms by which Th9 cells contribute to fighting this infection. The approach includes differentiating Th9 cells from other immune cells and testing their effectiveness in killing the bacteria in laboratory settings.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have received the Bacille Calmette-Guerin (BCG) vaccine or those with latent TB infection.
Not a fit: Patients who are currently infected with active tuberculosis may not benefit directly from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective vaccines or therapies for tuberculosis.
How similar studies have performed: While the role of Th1 cells in TB immunity has been well-studied, the investigation of Th9 cells is relatively novel and has not been extensively tested in this context.
Where this research is happening
Saint Louis, United States
- Saint Louis University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Hoft, Daniel F. — Saint Louis University
- Study coordinator: Hoft, Daniel F.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.